Blauvelt A et al
The once-daily application of Roflumilast 0.3 % foam (a phosphodiesterase 4 inhibitor) in adult and adolescent patients with seborrheic dermatitis showed significantly superior efficacy (79.5 %) to vehicle alone (58 %) after 8 weeks of treatment. The foam was found to be also welltolerated.
The advantages of this potential therapy for seborrheic dermatitis, in addition to its efficacy and safety (compared with, for example, steroids topical) lies also in the possibility of monotherapy and the vehicle, which is also suitable for treatment of areas covered by hair or hair.